Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Antiviral Research|May 28, 2014
Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patientsA Calcagno, L Marinaro, S Nozza, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 7, 2024
Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?J Cusato, A Manca, A Palermiti, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failureA Calcagno, N Pagani, A Ariaudo, et al.
International Journal of Antimicrobial Agents|January 29, 2020
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic SupplementationC Montrucchio, A De Nicolò, G D'Ettorre, et al.
British Journal of Clinical Pharmacology|February 15, 2018
Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administrationA Calcagno, C Pinnetti, A De Nicolò, et al.
The Pharmacogenomics Journal|November 9, 2018
Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?A Calcagno, M Fiumanò, D Zugna, et al.
Idcases|November 25, 2024
Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM)A R Buonomo, L Cattaneo, G Viceconte, et al.
The Journal of Antimicrobial Chemotherapy|March 17, 2011
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteersJ Ashby, L Garvey, O W Erlwein, et al.
Infection|December 3, 2011
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot studyS Bonora, A Calcagno, C Cometto, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 7, 2009
Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplantG Guaraldi, S Cocchi, A Motta, et al.
Pageof 4